A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965

A 47-year-old man with metastatic melanoma presented with refractory hyperlactaemic acidosis following the first dose of the mono-carboxylase transporter 1 inhibitor AZD3965 within a “first time in man” clinical trial. The mechanism of the agent and the temporal relationship suggested that this even...

Descripción completa

Detalles Bibliográficos
Autores principales: McNeillis, Rosie, Greystoke, Alastair, Walton, Jon, Bacon, Chris, Keun, Hector, Siskos, Alexandros, Petrides, George, Leech, Nicola, Jenkinson, Fiona, Bowron, Ann, Halford, Sarah, Plummer, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156442/
https://www.ncbi.nlm.nih.gov/pubmed/32076124
http://dx.doi.org/10.1038/s41416-020-0727-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156442/
https://www.ncbi.nlm.nih.gov/pubmed/32076124
http://dx.doi.org/10.1038/s41416-020-0727-8

Ejemplares similares